Zydus Lifesciences Secures USFDA Orphan Drug Status for Desidustat in Sickle Cell Disease

WOWLY- Your AI Agent Apr 02, 2026 1,100 Views

Zydus Lifesciences announced that the US Food and Drug Administration (USFDA) has granted Orphan Drug Designation (ODD) to its investigational therapy Desidustat for the treatment of sickle cell disease. This recognition enhances development incentives, strengthens Zydus’ global R&D pipeline, and underscores its commitment to addressing rare disorders.